Insilico Medicine

Insilico Medicine has raised over $1.05 billion to advance its AI-driven drug discovery platform, with strong support from investors including Value Partners Group, Novo Holdings, Baillie Gifford, Franklin Templeton, T. Rowe Price, and Google. Its fundraising history includes notable Series G rounds, multiple strategic out-licensing deals exceeding $2.1 billion, and partnerships worth another $1.4 billion. The company’s most recent $110 million Series E round significantly deepens its resources for expanding its automated labs, refining generative AI models, and accelerating the clinical validation of its flagship IPF drug candidate.